Introduction
The principal neutralization domain (PND) of human immunodeficiency virus type 1 (HIV-1) is contained between two disulphide-bonded cysteines at positions 296 and 335 in the third variable region of the envelope glycoprotein, gpl20, of HIV-1 strain BH10 (Rusche et al., 1988; Goudsmit et al., 1988; Palker et al., 1988; Leonard et al., 1990) . There is a conserved secondary structure element within this variable region, the type 2 /?-turn (LaRosa et al., 1990) , which comprises amino acids GPGR at the apex of the loop. The immunodominant PND binds and induces strain-specific neutralizing and cell fusion-inhibiting antibodies (Rusche et al., 1988) . Antibodies able to neutralize HIV-1 in vitro play an important role in the protective response Girard et al., 1991) . Anti-peptide anti-bodies do not neutralize the homologous virus invariably (Durda et al., 1990 ), for reasons not yet known. In an attempt to explain this property we studied eight monoclonal antibodies (MAbs), with neutralizing activity ranging from none to high, raised against a peptide representing the centre of the PND. To identify the cause of the varying neutralizing activity, we determined the concentration, affinity and fine specificity of each MAb. The fine specificity of each antibody was determined with the aid of Pepscan analysis; antibody reactivity was tested 0001-0292 © 1991 SGM using overlapping peptides and peptide analogues in which each amino acid position of the parent peptide was substituted by every naturally occurring amino acid.
Our results suggest that the neutralizing activity of each MAb correlates with its affinity for the PND peptide; furthermore, the differing affinity may be explained by the different side-chains contributing to the binding site and the secondary structure which the peptide adopts at the antigen-binding site. An MAb with high affinity recognizes the peptide in its favoured conformation, the type 2 fl-turn, and cross-reacts with the virus. MAbs with low affinity tolerate non-turn conformations and tend to cross-react poorly with the virus.
Methods
MAbs. MAbs 5023A, 5025A, 5021, 5025B, 5020 and 5023B were raised in mice, against a PND peptide with the amino acid sequence RIQRGPGRAFVTIGK (HIV-1 strain BH10) coupled to chicken ovalbumin with glutaraldehyde as described (Durda et al., 1990) . MAbs 5042A and 5042B were also raised in mice. against the same PND peptide conjugated to bovine thyroglobulin (BTG) by the water-soluble carbodiimide l-ethyl-3-(3-dimethylaminopropyl)-carbodiimide, as described (Durda et al., 1990) .
Neutralization assay. Syncytium inhibition assays using HIV-1 strain HX10 were performed by the method of Back et al. (1990) using C8166 cells as target cells and 56 TCIDso of virus purified from virus-producing H9 cells. The neutralizing activity against HIV-I HXI0 is expressed as the reciprocal of the highest ascites dilution giving 95 to 99% inhibition of syncytium formation.
ELISA. Antibody titres were measured in an indirect ELISA using microtitre plates coated with an excess of peptide RIQRGPGRAFV-TIGK (1 p.g/well) as described (Shapira et at., 1984; Suter, 1982) . The midpoint titre is defined as the reciprocal of the serum dilution giving 50% of the maximum absorbance value.
Affinity measurement. The affinity constants (Karl) for the PND peptides were determined using a slightly modified ELISA (Friguet et al., 1985; Stevens, 1987) to measure the concentration of free antibody when there was equilibrium between the MAb and peptide RIQRGP-GRAFVTIGK. This method produces an accurate Kafr provided that there is a linear correlation between the absorbance and the range of antibody concentration, and moreover that readjustment of the equilibrium is negligible in the liquid phase; both conditions were satisfied in these experiments. The equation Ao/(Ao -A) = 1 + Kd/a0 was used to calculate Kaff, where A 0 is the absorbance without blocking peptide; A is the absorbance with blocking peptide; a 0 is the peptide concentration; Kd is the dissociation constant.
HPLC analysis. The protein and specific IgG concentration were determined by HPLC analysis using a Bakerbond HPLC ABx column (7-75 mm x 10 cm) at 280 nm. The MAb was diluted 1:3 in MES buffer, injected and eluted with a gradient of sodium acetate (0% to 100%). Two MAbs purified from ascites fluid with a known protein concentration (Durda et al., 1990; P. J. Durda, unpublished) and one MAb contained in ascites fluid were assayed. The samples of the purified MAbs contained residual non-IgG protein. The reactivity of all the fractions collected was tested in ELISA to identify the IgG peak. The total integrated area was taken as a measure of total protein concentration and the area of the IgG fraction designated the IgG concentration.
Pepscan. Peptides were synthesized on polyethylene rods and tested with MAbs in an ELISA according to established procedures (Geysen et al., 1984 (Geysen et al., , 1985 . A set of overlapping peptides of between two and 18 residues with sequences derived from the region between amino acids 296 and 331, and a set of nonapeptides IQRGPGRAF and RGPGRAFVT, in which each amino acid was substituted by the other 19 naturally occurring amino acids, were synthesized.
Peptide synthesis. The peptide with the amino acid sequence RIQRGPGRAFVTIGK was synthesized using a slightly modified solid-phase synthesis method (Barany & Merrifield, 1980; Schaaper et al., 1989) . This preparation was used for determining the anti-peptide titre and for affinity measurements.
Results

Neutralizing activity of anti-peptide antibodies
The MAbs were tested for their neutralizing activity against HIV-1 HX10 using the method of Back et al. (1990) . As shown in Table 1 , the neutralizing activity varied between high and undetectable, which is consistent with observations from Western blot analysis (Durda et al., 1990 and unpublished results) .
Determination of antibody concentration by ELISA and HPLC
The hypothesis that neutralizing activity is dependent on MAb concentration [MAb] and affinity was tested (Stewart & Lew, 1985; Wilks et al., 1990; Devash et al., 1990) . Antibody concentration expressed as the midpoint titre (Methods), is shown in Table 1 . These titres correlated with the [MAb] , provided that the affinity was in the same range and the Kaff was less than 101° M -1 (Beatty et al., 1987) . The antibody concentration of two purified MAb preparations and one ascites fluid was also determined using reverse-phase HPLC analysis. The total protein concentration of the MAb preparations (P. J. Durda, unpublished) showed a linear relationship with the total integrated area of peaks found on HPLC analysis (data not shown). Midpoint titres, measured by ELISA, showed a linear relationship with the IgG area, 
5023B IQRG PG r a * Underlined residues, core of the epitope; capitals, major contribution according to reaction with overlapping peptides; lower case, minor contribution according to reaction with overlapping peptides; periods, no contribution; filled arrowheads, replaceable by few amino acids or none; open arrowheads, replaceable by many but not all amino acids. but not with the total protein area (Fig. 1) ; therefore, we assumed that the midpoint titre was a better measure of IgG concentration than total protein concentration. Using this linear correlation (Fig. 1) , the IgG concentration in other MAb samples was estimated (Table 1) .
The Kafr values were determined as described in Methods and are shown in Table 1 . A linear relationship was observed between loglo Karr and log10 of the neutralizing activity per mole (NT* = NT/[MAb]) (Fig.  2) . This relationship suggests that the biological activity is a function of the antibody concentration and the affinity for the antigen (NT ,~ Koyy x [MAb]); the product of these values is given in Table 1 .
Pepscan with overlapping peptides of variable length
MAbs raised against peptide RIQRGPGRAFVT!GK coupled to ovalbumin or BTG (Durda et al., 1990) were tested by Pepscan for their reactivity with overlapping peptides of the PND (amino acids 305 to 322) varying in length from two to 18 amino acids to determine the core and extent of the epitope recognized by each MAb. A representative example of the reactivity of an MAb with the overlapping peptides is shown in Fig. 3(a) . The tripeptide RAF is the smallest peptide with which MAb 5023A can react and is defined as the core of the epitope. The reactivity of MAb 5023A with tetrapeptide GRAF is threefold that with RAF, and therefore we assumed that the G residue contributes to binding. Such a comparison was made for each pair of peptides differing in length by one amino acid. The contribution of each amino acid flanking the core sequence to binding was calculated; for instance, the core sequence recognized by MAb 5023A is RAF, but residues R 311, P 313, G 314, T 319 and G 321 contribute to binding. The binding contribution is expressed as arbitrary units in Fig. 3 (b to  i) . Amino acids contained in the shortest reactive sequence (core of the antibody-binding site) and amino acids that contribute to MAb binding are listed in Table  2 .
Analysis of antibody specificity by Pepscan with substituted peptides
The role of individual amino acids in the peptide in antibody binding was determined further using peptide analogues which differed from the original reactive nonapeptide by only one amino acid. Each amino acid of the peptide was substituted in turn by all 19 naturally occurring amino acids. The reactivity of the MAbs with the replacement set of peptides for sequences IQRGP-GRAF or RGPGRAFVT is shown in Fig. 4. 
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An amino acid which can be substituted by few others is assumed to be important for antibody binding. Essential amino acids are listed in Table 2 . The data obtained with the replacement set of peptides and those obtained with overlapping peptides agreed well. However, when studied in detail, differences were found. The data obtained with overlapping peptides provided information on the size of the epitope and the contribution of flanking amino acids to antibody binding; the data obtained with the replacement peptides provided additional information about constraints on amino acid side-chains within the epitope.
For the five MAbs (5042A, 5021, 5025B, 5042B and 5020) that recognized an antigenic core on the major part of the turn, an analysis of the turn potential of the replacement peptides in Fig. 4 is summarized in Table 3 ; the analysis was based on the sequence preferences within the type 2 fl-turn (Fig. 5) (Wilmot & Thornton, 1988) . For each position we evaluated the effect on the flturn of a possible substitution, as shown in Fig. 4 . When tolerated amino acid substitutions (Fig. 4) did not correspond with the limited occurrence of amino acids at specific positions in known type 2 fl-turns (Fig. 5) , the preferred secondary structure was disrupted. Crucial amino acid substitutions which may affect conformation are listed in Table 3 ; boxed amino acids are those with a low turn propensity. The MAbs are ranked in order of decreasing affinity to illustrate that the MAbs with lower affinity bound to peptide analogues with low fl-turn potential.
MAb 5042A had a high affinity for the PND peptide (Table 1) . When the tolerated amino acid substitutions were studied in detail, the antibody bound only those peptide analogues in which the substituted amino acid did not affect the fl-turn potential (Fig. 4 and 5) . For instance, MAb 5042A bound to a peptide analogue which had an N residue at the third turn position; this agrees with the data in Fig. 5 , from which an N residue appears to be the second best amino acid in that position. The substitutions permitted at position 4 of the turn did not differ dramatically from the tolerated amino acids in Fig. 5 .
MAb 5021 had a high intermediate affinity for the PND peptide (Table 1 ). The tolerated amino acid substitutions showed that MAb 5021 reacted predominantly with peptides which have a high fl-turn potential, but the MAb also bound weakly to some peptide analogues having low fl-turn potential (Fig. 4 and 5) . For instance, this MAb bound to peptide analogues that had substitutions at the second turn position (V and N residues) and peptide analogues in which the third turn position is occupied by A, S or T residues; these substitutions have a low probability of occupying this turn position (Fig. 5) . MAb 5025B had a high intermediate affinity for the PND peptide. The results with the set of replacement peptides showed that, consistent with the high intermediate affinity, this MAb bound peptide analogues with high fl-turn potential, and reacted only weakly with a peptide analogue in which the second position is occupied by a V residue and the third position is occupied by an A residue, which has a low turn probability (Fig. 5) . MAb 5042B had a low intermediate affinity for the PND. According to the results with the replacement set of peptides, MAb 5042B bound strongly with peptide analogues with substitutions at the second (I, L and V residues) and fourth positions (P residue) of the turn, which have a low fl-turn potential (Fig. 5) .
MAb 5020, which had a low affinity for the PND peptide, reacted strongly with a peptide which had a P residue at the fourth position of the turn (Fig. 4) . This peptide has a very low turn potential (Fig. 5) .
MAbs 5023A, 5025A and 5023B were not included in this comparison because they did not react with the complete turn and are therefore independent of the type 2 fl-turn of this region; no evaluation of the constraints on the epitope can be made. These MAbs bind most strongly to sequences located on the C-or N-terminal side of the turn, as is indicated by the shortest reactive sequence (Table 2 ).
Discussion
The virus-neutralizing activity of an antibody may be expected to depend on its concentration, affinity and specificity. A linear relationship is found between NT* and the K, ff (Fig. 2) , and therefore a more meaningful expression of the neutralizing potential of an ascites fluid is obtained from the product of the concentration and the affinity of the antibody (Karl × [MAb]; Table 1 ). We found that all ascites fluids containing neutralizing antipeptide MAbs have Kafr × [MAb] values greater than 6000 and those containing non-neutralizing MAbs have a value lower than 1100. Our results show that the NT* value of the anti-peptide MAbs is proportional to the affinity, so we tried to explain the affinity of the peptides for the anti-peptide MAbs in terms of primary amino acid sequence using Pepscan analysis.
Irrespective of their biological activity, the antipeptide MAbs bind to the same region at the apex of the loop in the centre of the principal neutralization domain (PND). When studied in detail, each antibody shows a unique specificity for the individual amino acids in this region (Figs. 3 and 4) . This suggests that the striking difference in NT* and affinity of each MAb can be related to the fine structure of the binding site.
Antibody affinity is dependent on hydrophobic effects, solvent-modified electrostatics and loss of conformational entropy (Novotny et al., 1989) , so we tried to explain the affinity by studying two properties of the epitopes, i.e. the binding contribution of individual amino acids and the conformation of the epitope.
Certain amino acids contained within the epitope have a greater potential contribution to the total binding energy than others, e.g. R and aromatic residues (Novotny et al., 1989; Padlan, 1990; Saira Mian et al., 1991) . Aromatic residues have a large surface area, little rotational freedom in their side-chains and the aromatic ring can serve as a hydrogen bond acceptor (Atwood et al., 1991; Levitt & Perutz, 1988) . Therefore the high affinity of MAb 5023A for the PND peptide may be caused by interaction with amino acids like R and F ( Fig.  3b and 4a) ; MAb 5025A also interacts with F. In contrast to the Kaff of MAb 5023A, that of MAb 5025A is much lower, probably because it interacts with fewer amino acids. Moreover, MAb 5025A does not strictly require an aromatic amino acid at position 317, but also reacts with peptide analogues which have a nonaromatic, non-polar amino acid at position 317, which contributes less binding energy (Fig. 4d) (Novotny et al., 1989; Padlan, 1990; Saira Mian et al., 1991) . Thus, in a few cases, the difference in affinity can be explained by the binding contribution of specific amino acids.
In addition, the affinity of an MAb may depend on the conformation of the peptide to which it binds. Because a peptide has more conformational freedom than a protein, one might expect individual MAbs specific for a certain conformation to have a different capacity to cross-react with the native protein (Tainer et al., 1984) . Thus, MAbs with high affinity may recognize a conformation of the free PND peptide similar to that of the corresponding site in native gpl20. The type 2 fl-turn is predicted to be the most favoured structure of the PND (LaRosa et al., 1990; Wilmot & Thornton, 1988 ) and therefore we studied the ability of MAbs that recognize the primary sequence GPGR to bind peptides with amino acid substitutions affecting the fl-turn potential. Close inspection of the data in Fig. 4 suggests that high affinity antibodies bind only to amino acids with substitutions that do not affect the fl-turn, whereas low affinity antibodies tolerate amino acid substitutions that do affect the fl-turn (Table 3) .
In summary, the NT* correlates with the affinity for the PND, which is defined both by the epitope structure and the different contribution of individual amino acids to the total binding energy. Although our data set is too small to set general rules for the neutralizing activity of the antibodies raised against the PND peptide, the results do seem to explain the neutralizing activity of the antibodies described in this report. Generating antibodies against peptides will result in a variety of antibodies recognizing many different secondary structures. Because a strong immune response to an unrestrained peptide will not always result in a strong crossreactivity with the native protein, the data may help in the design of an effective, more restrained immunogen which will consistently induce high affinity antibodies to the native protein.
We wish to thank Douwe Kuperus, Wouter Puijk, Chitra Ramautarsing and Annet Steensma for their technical assistance, Wim Schaaper for the synthesis of the peptides, and Janke de Jager for typing the manuscript. This work was supported by the Dutch Foundation for Medical Research 'Medigon', grant no. 900-502-103.
